AC
AQST icon

Armistice Capital’s Aquestive Therapeutics AQST Stock Holding History

Armistice Capital’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,924,000
Closed -$7.93M – 343
2023
Q4 		$7.93M Sell
3,924,000
-876,000
-18% -$1.55M 0.11% 104
2023
Q3 		$7.34M Buy
4,800,000
+3,642,000
+315% +$6.26M 0.11% 99
2023
Q2 		$1.91M Buy
+1,158,000
New +$2.09M 0.03% 147

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Armistice Capital's AQST Position: Q1 2024 in Review

Armistice Capital sold out of Aquestive Therapeutics (AQST) in Q1 2024, closing a stake of 3,924,000 shares — an estimated $7.93M sold.

Armistice Capital first reported a position in AQST in Q2 2023 and held it in 3 quarters. The position peaked at $7.93M in Q4 2023. 97 funds tracked by Wall St. Rank hold AQST as of Q1 2024.

  • Armistice Capital reported no remaining Aquestive Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Armistice Capital sold 3,924,000 Aquestive Therapeutics shares in Q1 2024, an estimated $7.93M.
  • Armistice Capital first reported a position in Aquestive Therapeutics in Q2 2023 and held it in 3 quarters.
  • Armistice Capital's Aquestive Therapeutics position peaked at $7.93M in Q4 2023.
  • 97 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2024.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.